Category Archives: Hypertension

The global Pulmonary Arterial Hypertension (PAH) Drugsmarketis comprehensively and Insightful information in the report, taking into consideration various factors such as competition, regional growth, segmentation, and Pulmonary Arterial Hypertension (PAH) DrugsMarket size by value and volume. This is an excellent research study specially compiled to provide the latest insights into critical aspects of the Pulmonary Arterial Hypertension (PAH) Drugsmarket Continue reading →

An analysis report published by DataIntelo is an in-depth study and detailed information regarding the market size, market performance and market dynamics of the Pulmonary Arterial Hypertension Treatment. The report offers a robust assessment of the Global Pulmonary Arterial Hypertension Treatment Market to understand the current trend of the market and deduces the expected market trend for the Pulmonary Arterial Hypertension Treatment market for the forecast period Continue reading →

Can J Respir Ther. 2020 Nov 26;56:1-9. Continue reading →

SOUTH SAN FRANCISCO, Calif., Dec.4, 2020 /PRNewswire/ --Rigel Pharmaceuticals, Inc.(Nasdaq: RIGL) today announced that data related to TAVALISSE (fostamatinib disodium hexahydrate) tablets will be presented in two poster presentations at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held virtually December 5-8, 2020. The poster presentations will be made available on the event's website at https://www.hematology.org/meetings/annual-meetingon Saturday, December 5 at 7:30am PT. Rigel will present an analysis of long-term safety data on fostamatinib in more than 3,500 patients at various dosing regimens with immune thrombocytopenia (ITP) or rheumatoid arthritis (RA).Nonew safety signals norcumulative toxicity were observed with up to 62 months (5.2 years) of continuous treatment in ITP patients and up to 81 months (6.8 years) of continuous treatmentin RA patients Continue reading →

The Idiopathic Intracranial Hypertension Treatment Market grew in 2019, as compared to 2018, according to our report, Idiopathic Intracranial Hypertension Treatment Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Idiopathic Intracranial Hypertension Treatment Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025 Deep analysis about market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically Continue reading →

Day 29 of 30 Days of PH Topic: Dealing With The Elephant In The Room This is Skarlettes Story @skarletteisdead In December 2015, I was diagnosed with pulmonary hypertension and heart failure. My diagnosis did not come easily. Id been struggling for a long time and it took multiple doctors, three hospitals, seemingly endless tests, and a lot of hard conversations to finally find out what was wrong Continue reading →

This article was originally published on Diagnostic Imaging. According to a new study, coronavirus disease 2019 (COVID-19) positive patients who had hypertension and type 2 diabetes were more likely to experience the neurological complications, including bleeding in the brain and stroke, that come with the virus Continue reading →

Manufacturers Provide Improved Health Systems to Support Extracorporeal Therapies Growing incidences of acute kidney injury (AKI) have catalyzed the need for improved and quality treatment therapies in the continuous renal replacement therapy (CRRT) landscape. South East Asia and South America, individually, account for ~31% each, of the hospitalized population suffering from acute kidney injury in 2018. Read Report Overview - https://www.transparencymarketresearch.com/continuous-renal-replacement-therapy-market.html With the help of several clinical trials, continuous venovenous haemodiafiltration (CVVHDF) and the continuous venovenous heamofiltration (CVVHF) mode of therapies have helped improve the survival rates in patients suffering from sepsis-induced acute kidney injury (SAKI) Continue reading →

MannKind Corp. in Westlake Village has received its final $12.5 million milestone payment from United Therapeutics, the company said Thursday Continue reading →

This article was originally published here J Clin Hypertens (Greenwich). 2020 Nov 21. doi: 10.1111/jch.14101. Continue reading →